Brief: Spero Therapeutics Announces Second Quarter 2022 Operating Results And Provides Business Update
10/08/2022 22:13
Aug 10 (Reuters) - Spero Therapeutics Inc SPRO.O :
* SPERO THERAPEUTICS ANNOUNCES SECOND QUARTER 2022 OPERATING
RESULTS AND PROVIDES BUSINESS UPDATE
* SPERO - BELIEVES EXISTING CASH, CASH EQUIVALENTS &
MARKETABLE
SECURITIES, WILL BE SUFFICIENT TO FUND PLANNED OPERATING
EXPENSES & CAPEX INTO LATE 2023
* SPERO THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.87
Source text for Eikon: ID:nGNX3RwRDc
Further company coverage: SPRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)